NCT03086733View on ClinicalTrials.gov

Phase II Lung Metcore - Preoperative Metformin for Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

August 31, 2020

Conditions
Non Small Cell Lung CancerLung Cancer
Interventions
DRUG

Metformin

850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21

Trial Locations (2)

M5G 2C4

Toronto General Hospital, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03086733 - Phase II Lung Metcore - Preoperative Metformin for Lung Cancer | Biotech Hunter | Biotech Hunter